Epidemiologia i leczenie krótkowzroczności na świecie

Grzybowski, Andrzej; Szwajkowska, Maria

Journal

OphthaTherapy

2017 | 4 | 3 | 129-135

Article title

Epidemiologia i leczenie krótkowzroczności na świecie

Authors

Andrzej Grzybowski , Maria Szwajkowska

Content

Full texts:

1.OPT_3-2017_Epidemiologia i leczenie krótkowzroczności.pdf

Download

Title variants

Epidemiology and treatment of myopia worldwide

Languages of publication

Abstracts

Obecnie 1,6 mld ludzi na świecie jest dotkniętych krótkowzrocznością; w 2050 r. połowa ludzkości będzie miała tę wadę wzroku. Rozpowszechnienie krótkowzroczności, zwłaszcza wśród dzieci i młodzieży, każe nam zwrócić uwagę na ten problem oraz znaleźć sposoby zapobiegania jej i leczenia. Krótkowzroczność postępująca prowadzi do takich powikłań, jak jaskra, zaćma, odwarstwienie siatkówki czy makulopatia związana z krótkowzrocznością, które są przyczynami znacznego obniżenia ostrości wzroku. Metody leczenia krótkowzroczności dzielą się na „tradycyjne” i farmakologiczne. Najlepsze efekty przynosi podawanie kropli z atropiną, a efekt tego leczenia najdłużej utrzymuje się po zastosowaniu stężenia 0,01%, które daje równocześnie najmniejsze efekty uboczne. Wiele rozpowszechnionych metod, jak niedokorygowanie szkieł okularowych, nie przynosi rezultatów.

Nowadays, 1.6 billion people worldwide struggle with myopia; in 2050, half of the world's population will be impacted by the condition. Increased incidence of myopia, especially among children and youngsters, forces us to pay greater attention to the problem and look for solutions on how to prevent and treat the defect. Progressive myopia leads to such complications as glaucoma, cataract, retinal detachment or myopic macular degeneration related to myopia, all of which lead to a significant decrease in visual acuity. Myopia treatment methods can be divided into “traditional” and pharmacological. The best outcome may be achieved by dosing drops with atropine, and treatment effects last longest, if the concentration of 0.01% is used, causing the fewest side effects at the same time. Many widespread methods, such as undercorrected spectacles, do not bring effect.

Keywords

krople z atropiną krótkowzroczność leczenie farmakologiczne krótkowzroczności metody leczenia krótkowzroczności

Discipline

MEDICINE: MEDICINE

Publisher

Medical Education

Journal

OphthaTherapy

Year

2017

Volume

Issue

Pages

129-135

Physical description

Contributors

author

Andrzej Grzybowski

ae.grzybowski@gmail.com

1. Oddział Okulistyczny, Wielospecjalistyczny Szpital Miejski w Poznaniu. 2. Katedra Okulistyki, Uniwersytet Warmińsko-Mazurski w Olsztynie

author

Maria Szwajkowska

Oddział Chirurgii Głowy i Szyi, Wojewódzki Specjalistyczny Szpital Dziecięcy w Olsztynie

References

1. Fu Y, Geng D, Liu H, Che H. Myopia and/or longer axial length are protective against diabetic retinopathy: a meta-analysis. Acta Ophthalmol 2016; 94: 346-352.
2. Holden BA, Jong M, Davis S, et al. Nearly 1 billion myopes at risk of myopia-related sight-threatening conditions by 2050 – time to act now. Clin Exp Optom 2015; 98: 491-493.
3. Loughman J, Flitcroft DI. The acceptability and visual impact of 0,01% atropine in Caucasian population. Br J Ophthalmol 2016; 100: 1525-1529.
4. Janowski M, Bulte JWM, Handa JT, et al. Concise Review: Using Stem Cells to Prevent the Progression of Myopia – A Concept. Stem Cells 2015; 33: 2104-2113.
5. Polling JR, Kok RGW, Tideman JWL, et al. Effectiveness study of atropine for progressive myopia in Europeans. Eye 2016; 30: 998-1004.
6. Warner N. Update on myopia. Curr Opin Ophthalmol 2016; 27: 402-406.
7. Rudnicka AR, Kapetanakis VV, Wathern AK, et al. Global variations and time trends in the prevalence of childhood myopia, a systematic review and quanitative meta-analysis: implications for aetiology and early prevention. Br J Ophthalmol 2016; 100: 882-890.
8. Williams KM, Bertelsen G, Cumberland P, et al. Increasing Prevalence of Myopia in Europe and the Impact of Education. Ophthalmology 2015; 122: 1489-1497.
9. Williams KM, Verhoeven VJ, Cumberland P, et al. Prevalence of refractive error in Europe: the European Eye Epidemiology (E(3)) Consortium. Eur J Epidemiol 2015; 30: 305-315.
10. Read SA, Collins MJ, Vincent SJ. Light Exposure and Eye Growth in Childhood. Invest Ophthalmol Vis Sci 2015; 56: 6679-6687.
11. Huang J, Wen D, Wang Q, et al. Efficacy Comparison of 16 Interventions for Myopia Control in Children. Ophthalmology 2016; 123: 697-708.
12. Holden BA, Fricke TR, Wilson DA, et al. Global Prevalence of Myopia and High Myopia and Temporal Trends from 2000 through 2050. Ophthalmology 2016; 123: 1036-1042.
13. Schen ZM, Zhang ZY, Zhang LY, et al. Posterior scleral reinforcement combined with patching therapy for pre-school children with unilateral high myopia. Graefes Arch Clin Exp Ophthalmol 2015; 253: 1391-1395.
14. Sankaridurg P, Holden B, Smith E, et al. Decrease in rate of myopia progression with a contact lens designed to reduce relative peripheral hyperopia: one-year results. Invest Ophthalmol Vis Sci 2011; 52: 9362-9367.
15. Radhakrishnan H, Allen PM, Calver RI, et al. Peripheral Refractive Changes Associated with Myopia Progression. Invest Ophthalmol Vis Sci 2013; 52: 1573-1581.
16. Cheng D, Woo GC, Drobe B, Schmid KL. Effect of bifocal and prismatic bifocal spectacles on myopia progression in children: threeyear results of a randomized clinical trial. JAMA Ophthalmol 2014; 132: 258-264.
17. Si JK, Tang K, Bi HS, et al. Orthokeratology for myopia control: a meta-analysis. Optom Vis Sci 2015; 92: 252-257.
18. Hiraoka T, Kakita T, Okamoto F, et al. Long-term effect of overnight orthokeratology on axial lenght elongation in childhood myopia: a 5-year follow-up study. Invest Ophthalmol Vis Sci 2012; 53: 3913-3919.
19. Siatkowski RM, Cotter S, Miller JM, et al. Safety and Efficacy of 2% Pirenzepine Ophthalmic Gel in Children With Myopia. Arch Ophthalmol 2004; 122: 1667-1674.
20. Hasket D. On the Atropine Treatment of Acquired and Progressive Myopia. Trans Am Ophthalmol Soc 1874; 2: 139-154.
21. Luedde WH. Monocular Cycloplegia for the Control of Myopia. Am J Ophthalmol 1932; 15: 603-610.
22. Bedrossian R. The Effect of Atropine on Myopia. Ophthalmology 1979; 86: 713-717.
23. Dyer JA. Role of Cycloplegics in Progressive Myopia. Ophthalmology 1979; 86: 692-694.
24. Bedrossian RH. The Effect of Atropine on Myopia. Ann Ophthalmol 1971; 3: 891-897.
25. Gimbel HV. The Control of Myopia with Atropine. Can J Ophthalmol 1973; 8: 527-532.
26. Kennedy RH. Progression of Myopia. Trans Am Ophthalmol Soc 1995; 93: 755-800.
27. Chua WH, Balakrishnan V, Chan YH, et al. Atropine for the Treatment of Childhood Myopia. Ophthalmology 2006; 113: 2285-2291.
28. Chia A, Chua WH, Cheung YB, et al. Atropine for the Treatment of Childhood Myopia: Safety and Efficacy of 0,5%, 0,1%, and 0,01% Doses (Atropine for the /treatment of Myopia 2). Ophthalmology 2012; 119: 347-354.
29. Tong L, Huang XL, Koh ALT, et al. Atropine for the Treatment of Childhood Myopia: Effect on Myopia Progression after Cassation of Atropine. Ophthalmology 2009; 116: 572-579.
30. Chia A, Chua WH, Wen L, et al. Atropine for the Treatment of Childhood Myopia: Changes after Stopping Atropine 0,01%, 0,1% and 0,5%. Am J Ophthalmol 2014; 157: 451-457.

Document Type

article

Publication order reference

Identifiers

YADDA identifier

bwmeta1.element.psjd-781230d1-7efe-4b2b-9e96-8b6f431d5133